Shalini C. Reshmi

Dr. Shalini C. Reshmi


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2017 in Blood
Verified
Journal Article
Open access
PDF file
Shalini C. ReshmiShalini C. Reshmi
Shalini C. Reshmi
RHRichard C Harvey
Richard C Harvey
KRKathryn G Roberts
Kathryn G Roberts
ESEileen Stonerock
Eileen Stonerock
ASAmy Smith
Amy Smith
SHStephen P Hunger
Stephen P Hunger
Key Points: Ph-like ALL is characterized by a diverse array of genetic alterations activating cytokine receptor and tyrosine kinase signaling. Pediatric patients with Ph-like ALL can be identified in real time for effective treatment stratification.

5 March 2018 in Blood Advances
Verified
Journal Article
Closed access
TTThai Hoa Tran
Thai Hoa Tran
MHMarian H. Harris
Marian H. Harris
JNJonathan V. Nguyen
Jonathan V. Nguyen
TBTraci M. Blonquist
Traci M. Blonquist
KSKristen E. Stevenson
Kristen E. Stevenson
LSLewis B. Silverman
Lewis B. Silverman
Key Points: Fifteen percent of NCI high-risk, Ph-negative, B-ALL patients harbored a kinase-activating fusion, and often associated with IKZF1 deletion. IKZF1 deletion represents an independent prognostic factor of poor outcomes, regardless of fusion-positivity.

1 May 2017 in Leukemia Research
Verified
Journal Article
Closed access
SPShiven Patel
Shiven Patel
CMClinton C. Mason
Clinton C. Mason
MGMartha J. Glenn
Martha J. Glenn
CPChristian N. Paxton
Christian N. Paxton
SSSara T. South
Sara T. South
RMRodney R. Miles
Rodney R. Miles

1 July 2014 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
LWLauren C. Walters-Sen
Lauren C. Walters-Sen
DTDevon Lamb Thrush
Devon Lamb Thrush
SHScott E. Hickey
Scott E. Hickey
SHSayaka Hashimoto
Sayaka Hashimoto
Shalini C. ReshmiShalini C. Reshmi
Shalini C. Reshmi
CACaroline Astbury
Caroline Astbury

1 September 2013 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
ERElena A. Repnikova
Elena A. Repnikova
JRJill A. Rosenfeld
Jill A. Rosenfeld
ABAndrea Bailes
Andrea Bailes
CWCecilia Weber
Cecilia Weber
LELinda Erdman
Linda Erdman
RPRobert E. Pyatt
Robert E. Pyatt

27 October 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FHFlorette K. Hazard
Florette K. Hazard
ATAngus M.S. Toland
Angus M.S. Toland
STSerena Y. Tan
Serena Y. Tan
BCBill Chiu
Bill Chiu
NINaohiko Ikegaki
Naohiko Ikegaki
HSHiroyuki Shimada
Hiroyuki Shimada
Purpose: Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC). Experimental Design: The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors. Results: This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC. Conclusions: The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.